{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:34:29Z","timestamp":1794490469246,"version":"4.9.1"},"reference-count":113,"publisher":"The Microbiological Society of Korea","issue":"8","license":[{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Microbiol."],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s12275-020-0285-z","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T10:06:10Z","timestamp":1595844370000},"page":"633-647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Recent advances in the development of \u03b2-lactamase inhibitors"],"prefix":"10.71150","volume":"58","author":[{"given":"Shivakumar S.","family":"Jalde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Kyung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4586","published-online":{"date-parts":[[2020,7,27]]},"reference":[{"key":"285_CR1","volume-title":"European Congress of Clinical Microbiology and Infectious Diseases (28th ECCMID) Madrid Spain","author":"AF Aboklaish","year":"2018","unstructured":"Aboklaish, A.F., Okujava, R., El-Bouseary, M., Zampaloni, C., Najera, I., Bradley, K., Walsh, T.R., and Tyrrell, J.M. 2018. Nacubactam antibacterial activity alone and in combination with \u03b2-lactam antibiotics against contemporary Enterobacteriaceae clinical isolates. European Congress of Clinical Microbiology and Infectious Diseases (28th ECCMID) Madrid Spain, Abs. P1034."},{"key":"285_CR2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijantimicag.2011.09.012","volume":"39","author":"Z Akta\u015f","year":"2012","unstructured":"Akta\u015f, Z., Kayacan, C., and Oncul, O. 2012. In vitro activity of avibactam (NXL104) in combination with \u03b2-lactams against Gram-negative bacteria, including OXA-48 \u03b2-lactamase-producing Klebsiella pneumoniae. Int. J. Antimicrob. Agents39, 86\u201389.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"285_CR3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1128\/AAC.48.2.533-537.2004","volume":"48","author":"M Alvarez","year":"2004","unstructured":"Alvarez, M., Tran, J.H., Chow, N., and Jacoby, G.A. 2004. Epidemiology of conjugative plasmid-mediated AmpC \u03b2-lactamases in the United States. Antimicrob. Agents Chemother.48, 533\u2013537.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1098\/rstb.1980.0049","volume":"289","author":"RP Ambler","year":"1980","unstructured":"Ambler, R.P. 1980. The structure of \u03b2-lactamases. Philos. Trans. R. Soc. Lond. B Biol. Sci.289, 321\u2013331.","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"285_CR5","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.bcp.2007.05.021","volume":"74","author":"C Bebrone","year":"2007","unstructured":"Bebrone, C. 2007. Metallo-\u03b2-lactamases (Classification, activity, genetic organization, structure, Zinc coordination) and their superfamily. Biochem. Pharmacol.74, 1686\u20131701.","journal-title":"Biochem. Pharmacol."},{"key":"285_CR6","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1016\/j.bmcl.2008.05.045","volume":"18","author":"J Beck","year":"2008","unstructured":"Beck, J., Sauvage, E., Charlier, P., and Marchand-Brynaert, J. 2008. 2-Aminopropane-1, 2, 3-tricarboxylic acid: synthesis and co-crystallization with the class A \u03b2-lactamase BS3 of Bacillus licheniformis. Bioorg. Med. Chem. Lett.18, 3764\u20133768.","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"285_CR7","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1128\/AAC.00206-15","volume":"59","author":"DJ Biedenbach","year":"2015","unstructured":"Biedenbach, D.J., Kazmierczak, K., Bouchillon, S.K., Sahm, D.F., and Bradford, P.A. 2015. In vitro activity of Aztreonam-Avibactam against a global collection of Gram-negative pathogens from 2012 and 2013. Antimicrob. Agents Chemother.59, 4239\u20134248.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR8","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1086\/504477","volume":"43","author":"RA Bonomo","year":"2006","unstructured":"Bonomo, R.A. and Szabo, D. 2006. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin. Infect. Dis.43, S49\u2013S56.","journal-title":"Clin. Infect. Dis."},{"key":"285_CR9","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/nchem.2110","volume":"6","author":"J Brem","year":"2014","unstructured":"Brem, J., van Berkel, S.S., Aik, W., Rydzik, A.M., Avison, M.B., Pettinati I., Umland, K.D., Kawamura, A., Spencer, J., Claridge, T.D.W., et al. 2014. Rhodanine hydrolysis leads to potent thioenolate mediated metallo-\u03b2-lactamase inhibition. Nat. Chem.6, 1084\u20131090.","journal-title":"Nat. Chem."},{"key":"285_CR10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1128\/AAC.01335-15","volume":"60","author":"J Brem","year":"2016","unstructured":"Brem, J., van Berkel, S.S., Zollman, D., Lee, S.Y., Gileadi, O., McHugh, P.J., Walsh, T.R., McDonough, M.A., and Schofield, C.J. 2016. Structural basis of metallo-\u03b2-lactamase inhibition by captopril stereoisomers. Antimicrob. Agents Chemother.60, 142\u2013150.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR11","volume-title":"\u03b2-Lactamase inhibitors","author":"CJ Burns","year":"2017","unstructured":"Burns, C.J., Daigle, D., Liu, B., Jackson, R.W., Hamrick, J., McGarry, D., Pevear, D.C., and Trout, R.E.L. 2017. \u03b2-Lactamase inhibitors. US Patent 9637504 B2, Venatorx Pharmaceuticals Inc., Philadelphia, USA."},{"key":"285_CR12","doi-asserted-by":"crossref","first-page":"e01076","DOI":"10.1128\/AAC.01076-18","volume":"62","author":"K Bush","year":"2018","unstructured":"Bush, K. 2018. Past and present perspectives on \u03b2-lactamases. Antimicrob. Agents Chemother.62, e01076\u201318.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41579-019-0159-8","volume":"17","author":"K Bush","year":"2019","unstructured":"Bush, K. and Bradford, P.A. 2019. Interplay between \u03b2-lactamases and new \u03b2-lactamases inhibitors. Nat. Rev. Microbiol.17, 295\u2013306.","journal-title":"Nat. Rev. Microbiol."},{"key":"285_CR14","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","volume":"54","author":"K Bush","year":"2010","unstructured":"Bush, K. and Jacoby, G.A. 2010. Updated functional classification of \u03b2-lactamases. Antimicrob. Agents Chemother.54, 969\u2013976.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR15","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1128\/AAC.39.6.1211","volume":"39","author":"K Bush","year":"1995","unstructured":"Bush, K., Jacoby, G.A., and Medeiros, A.A. 1995. A functional classification scheme for \u03b2-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother.39, 1211\u20131233.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR16","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1128\/AAC.37.4.851","volume":"37","author":"K Bush","year":"1993","unstructured":"Bush, K., Macalintal, C., Rasmussen, B.A., Lee, V.J., and Yang, Y. 1993. Kinetic interactions of tazobactam with \u03b2-lactamases from all major structural classes. Antimicrob. Agents Chemother.37, 851\u2013858.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR17","doi-asserted-by":"crossref","first-page":"e02260","DOI":"10.1128\/AAC.02260-16","volume":"61","author":"ST Cahill","year":"2017","unstructured":"Cahill, S.T., Cain, R., Wang, D.Y., Lohans, C.T., Wareham, D.W., Oswin, H.P., Mohammed, J., Spencer, J., Fishwick, C.W.G., Mc-Donough, M.A., et al. 2017. Cyclic boronates inhibit all classes of \u03b2-lactamases. Antimicrob. Agents Chemother.61, e02260\u201316.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR18","doi-asserted-by":"crossref","first-page":"7267","DOI":"10.1021\/acs.jmedchem.7b00407","volume":"60","author":"AY Chen","year":"2017","unstructured":"Chen, A.Y., Thomas, P.W., Stewart, A.C., Bergstrom, A., Cheng, Z., Miller, C., Bethel, C.R., Marshall, S.H., Credille, C.V., Riley, C.L., et al. 2017. Dipicolinic acid derivatives as inhibitors of New Delhi metallo-\u03b2-lactamase-1. J. Med. Chem.60, 7267\u20137283.","journal-title":"J. Med. Chem."},{"key":"285_CR19","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1128\/AAC.01682-10","volume":"55","author":"DM Citron","year":"2011","unstructured":"Citron, D.M., Tyrrell, K.L., Merriam, V., and Goldstein, E.J.C. 2011. In vitro activity of Ceftazidime-NXL104 against 396 strains of \u03b2-lactamase-producing anaerobes. Antimicrob. Agents Chemother.55, 3616\u20133620.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR20","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.2146\/ajhp150049","volume":"72","author":"D Cluck","year":"2015","unstructured":"Cluck, D., Lewis, P., Stayer, B., Spivey, J., and Moorman, J. 2015. Ceftolozane-tazobactam: a new-generation cephalosporin. Am. J. Health Syst. Pharm.72, 2135\u20132146.","journal-title":"Am. J. Health Syst. Pharm."},{"key":"285_CR21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.mib.2011.07.026","volume":"14","author":"K Coleman","year":"2011","unstructured":"Coleman, K. 2011. Diazabicyclooctanes (DBOs): a potent new class of non-\u03b2-lactam \u03b2-lactamase inhibitors. Curr. Opin. Microbiol.14, 550\u2013555.","journal-title":"Curr. Opin. Microbiol."},{"key":"285_CR22","doi-asserted-by":"crossref","first-page":"7997","DOI":"10.1021\/jm401053m","volume":"56","author":"JA Day","year":"2013","unstructured":"Day, J.A. and Cohen, S.M. 2013. Investigating the selectivity of metalloenzyme inhibitors. J. Med. Chem.56, 7997\u20138007.","journal-title":"J. Med. Chem."},{"key":"285_CR23","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1001\/archinte.1991.00400050040010","volume":"151","author":"LA Dever","year":"1991","unstructured":"Dever, L.A. and Dermody, T.S. 1991. Mechanisms of bacterial resistance to antibiotics. Arch. Intern. Med.151, 886\u2013895.","journal-title":"Arch. Intern. Med."},{"key":"285_CR24","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s40265-018-0966-7","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon, S. 2018. Meropenem\/Vaborbactam: a review in complicated urinary tract infections. Drugs78, 1259\u20131270.","journal-title":"Drugs"},{"key":"285_CR25","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1093\/cid\/ciz830","volume":"69","author":"Y Doi","year":"2019","unstructured":"Doi, Y. 2019. Treatment options for carbapenem-resistant Gram-negative bacterial infections. Clin. Infect. Dis.69, S565\u2013S575.","journal-title":"Clin. Infect. Dis."},{"key":"285_CR26","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1128\/AAC.00743-09","volume":"54","author":"SM Drawz","year":"2010","unstructured":"Drawz, S.M., Bethel, C.R., Doppalapudi, V.R., Sheri, A., Pagadala, S.R.R., Hujer, A.M., Skalweit, M.J., Anderson, V.E., Chen, S.G., Buynak, J.D., et al. 2010. Penicillin sulfone inhibitors of class D \u03b2-lactamases. Antimicrob. Agents Chemother.54, 1414\u20131424.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/CMR.00037-09","volume":"23","author":"SM Drawz","year":"2010","unstructured":"Drawz, S.M. and Bonomo, R.A. 2010. Three decades of \u03b2-lactamase inhibitors. Clin. Microbiol. Rev.23, 160\u2013201.","journal-title":"Clin. Microbiol. Rev."},{"key":"285_CR28","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1128\/AAC.00826-13","volume":"58","author":"SM Drawz","year":"2014","unstructured":"Drawz, S.M., Papp-Wallace, K.M., and Bonomo, R.A. 2014. New \u03b2-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob. Agents Chemother.58, 1835\u20131846.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR29","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","volume":"63","author":"DV Duin","year":"2016","unstructured":"Duin, D.V. and Bonomo, R.A. 2016. Ceftazidime\/Avibactam and Ceftolozane\/Tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations. Clin. Infect. Dis.63, 234\u2013241.","journal-title":"Clin. Infect. Dis."},{"key":"285_CR30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.idc.2016.02.004","volume":"30","author":"DV Duin","year":"2016","unstructured":"Duin, D.V. and Paterson, D. 2016. Multidrug-resistant bacteria in the community: trends and lessons learned. Infect. Dis. Clin. North Am.30, 377\u2013390.","journal-title":"Infect. Dis. Clin. North Am."},{"key":"285_CR31","doi-asserted-by":"crossref","first-page":"17104","DOI":"10.1038\/nmicrobiol.2017.104","volume":"2","author":"TF Durand-R\u00e9ville","year":"2017","unstructured":"Durand-R\u00e9ville, T.F., Guler, S., Comita-Prevoir, J., Chen, B., Bifulco, N., Huynh, H., Lahiri, S., Shapiro, A.B., McLeod, S.M., Carter, N.M., et al. 2017. ETX2514 is a broad-spectrum \u03b2-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat. Microbiol.2, 17104.","journal-title":"Nat. Microbiol."},{"key":"285_CR32","doi-asserted-by":"crossref","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","volume":"288","author":"DE Ehmann","year":"2013","unstructured":"Ehmann, D.E., Jahic, H., Ross, P.L., Gu, R.F., Hu, J., Durand-R\u00e9ville, T.F., Lahiri, S., Thresher, J., Livchak, S., Gao, N., et al. 2013. Kinetics of Avibactam inhibition against Class A, C, and D \u03b2-lactamases. J. Biol. Chem.288, 27960\u201327971.","journal-title":"J. Biol. Chem."},{"key":"285_CR33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/14787210.2018.1447381","volume":"16","author":"DR Giacobbe","year":"2018","unstructured":"Giacobbe, D.R., Bassetti, M., De Rosa, F.G., Del Bono, V., Grossi, P.A., Menichetti, F., Pea, F., Rossolini, G.M., Tumbarello, M., Viale, P., et al. 2018. Ceftolozane\/tazobactam: place in therapy. Expert Rev. Anti. Infext. Ther.16, 307\u2013320.","journal-title":"Expert Rev. Anti. Infext. Ther."},{"key":"285_CR34","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/14787210.5.3.365","volume":"5","author":"A Gin","year":"2007","unstructured":"Gin, A., Dilay, L., Karlowsky, J.A., Walkty, A., Rubinstein, E., and Zhanel, G.G. 2007. Piperacillin-tazobactam: a \u03b2-lactam\/\u03b2-lactamase inhibitor combination. Expert Rev. Anti. Infect. Ther.5, 365\u2013383.","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"285_CR35","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1016\/j.bmcl.2017.08.027","volume":"27","author":"C Gonz\u00e1lez-Bello","year":"2017","unstructured":"Gonz\u00e1lez-Bello, C. 2017. Antibiotic adjuvants-a strategy to unlock bacterial resistance to antibiotics. Bioorg. Med. Chem. Lett.27, 4221\u20134228.","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"285_CR36","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1021\/acs.jmedchem.9b01279","volume":"63","author":"C Gonz\u00e1lez-Bello","year":"2020","unstructured":"Gonz\u00e1lez-Bello, C., Rodr\u00edguez, D., Pernas, M., Rodr\u00edguez, A., and Colch\u00f3n, E. 2020. \u03b2-Lactamase inhibitors to restore the efficacy of antibiotics against superbugs. J. Med. Chem.63, 1859\u20131881.","journal-title":"J. Med. Chem."},{"key":"285_CR37","volume-title":"European Congress of Clinical Microbiology and Infectious Diseases (29th ECCMID), Amsterdam, Netherlands","author":"E Gordon","year":"2019","unstructured":"Gordon, E., Duncton, M., Lal, R., and Trias, J. 2019. Oral prodrugs of avibactam, medicinal chemistry, and synthesis of ARX1796. European Congress of Clinical Microbiology and Infectious Diseases (29th ECCMID), Amsterdam, Netherlands. Poster P1159."},{"key":"285_CR38","first-page":"e00642","volume":"61","author":"G Haider","year":"2017","unstructured":"Haider, G., Clancy, C.J., Chen, L., Samanta, P., Shields, R.K., Kreiswirth, B.N., Nguyen, M.H. 2017. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. Antimicrob. Agents Chemother.61, e00642\u201317.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR39","volume-title":"Boronic acid derivatives and therapeutic uses thereof","author":"SJ Hecker","year":"2020","unstructured":"Hecker, S.J., Reddy, R.K., Glinka, T., and Rodny, O. 2020a. Boronic acid derivatives and therapeutic uses thereof. US Patent 1057-0159B2, Qpex Biopharma, Inc., San Diego, USA."},{"key":"285_CR40","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01976","volume-title":"J. Med. Chem.","author":"SJ Hecker","year":"2020","unstructured":"Hecker, S.J., Reddy, R.K., Lomovskaya, O., Griffith, D.C., Rubio-Aparicio, D., Nelson, K., Tsivkovski, R., Sun, D., Sabet, M., Tarazi, Z., et al. 2020b. Discovery of cyclic boronic acid QPX7728, an ultrabroad-spectrum inhibitor of serine and metallo-\u03b2-lactamases. J. Med. Chem. DOI: https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01976."},{"key":"285_CR41","doi-asserted-by":"crossref","first-page":"20659","DOI":"10.1074\/jbc.M212581200","volume":"278","author":"U Heinz","year":"2003","unstructured":"Heinz, U., Bauer, R., Wommer, S., Meyer-Klaucke, W., Papamichaels, C., Bateson, J., and Adolph, H.W. 2003. Coordination geometries of metal ions in D- or L-captopril-inhibited metallo-\u03b2-lactamases. J. Biol. Chem.278, 20659\u201320666.","journal-title":"J. Biol. Chem."},{"key":"285_CR42","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/AAC.48.5.1586-1592.2004","volume":"48","author":"PG Higgins","year":"2004","unstructured":"Higgins, P.G., Wisplinghoff, H., Stefanik, D., and Seifert, H. 2004. In vitro activities of the \u03b2-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with \u03b2-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Antimicrob. Agent Chemother.48, 1586\u20131592.","journal-title":"Antimicrob. Agent Chemother."},{"key":"285_CR43","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1128\/AAC.05927-11","volume":"56","author":"EB Hirsch","year":"2012","unstructured":"Hirsch, E.B., Ledesma, K.R., Chang, K.T., Schwartz, M.S., Motyl, M.R., and Tam, V.H. 2012. In vitro activity of MK-7655, a novel \u03b2-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob. Agents Chemother.56, 3753\u20133757.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR44","first-page":"611","volume":"62","author":"KB Holten","year":"2000","unstructured":"Holten, K.B. and Onusko, E.M. 2000. Appropriate prescribing of oral \u03b2-lactam antibiotics. Am. Fam. Physician.62, 611\u2013620.","journal-title":"Am. Fam. Physician."},{"key":"285_CR45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1021\/acsinfecdis.7b00168","volume":"4","author":"R Iyer","year":"2018","unstructured":"Iyer, R., Moussa, S.H., Durand-R\u00e9ville, T.F., Tommasi, R., and Miller, A. 2018. Acinetobacter baumanni OmpA is a selective antibiotic permeant porin. ACS Infect. Dis.4, 373\u2013381.","journal-title":"ACS Infect. Dis."},{"key":"285_CR46","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/CMR.00036-08","volume":"22","author":"GA Jacoby","year":"2009","unstructured":"Jacoby, G.A. 2009. AmpC \u03b2-lactamases. Clin. Microbiol. Rev.22, 161\u2013182.","journal-title":"Clin. Microbiol. Rev."},{"key":"285_CR47","doi-asserted-by":"crossref","first-page":"ofaa014","DOI":"10.1093\/ofid\/ofaa014","volume":"7","author":"BM Jones","year":"2020","unstructured":"Jones, B.M., Huelfer, K., and Bland, C.M. 2020. Clinical and safety evaluation of continuously infused ceftolozane\/tazobactam in the outpatient setting. Open Forum Infect. Dis.7, ofaa014.","journal-title":"Open Forum Infect. Dis."},{"key":"285_CR48","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1128\/AAC.01483-13","volume":"58","author":"CM June","year":"2014","unstructured":"June, C.M., Vallier, B.C., Bonomo, R.A., Leonard, D.A., and Powers, R.A. 2014. Structural origins of oxacillinase specificity in class D \u03b2-lactamases. Antimicrob. Agents Chemother.58, 333\u2013341.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR49","volume-title":"Abstracts of the Twenty-fifth European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen (ESCMID), Basel, Switzerland","author":"A Kano","year":"2015","unstructured":"Kano, A., Koresawa, T., Matsumoto, K., Ouchi, S., and Kondo, K. 2015. First in human study to assess safety, tolerability and pharmacokinetics of \u03b2-lactamase inhibitor OP0595. Abstracts of the Twenty-fifth European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen (ESCMID), Basel, Switzerland. Abs. P0236."},{"key":"285_CR50","first-page":"735","volume":"72","author":"MK Kim","year":"2017","unstructured":"Kim, M.K., An, Y.J., Na, J.H., Seol, J.H., Ryu, J.Y., Lee, J.W., Kang, L.W., Chung, K.M., Lee, J.H., Moon, J.H., et al. 2017. Structural and mechanistic insights into the inhibition of class C \u03b2-lactamases through the adenylylation of the nucleophilic serine. J. Antimicrob. Chemother. 72, 735\u2013743.","journal-title":"J. Antimicrob. Chemother."},{"key":"285_CR51","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1365-2958.2006.05146.x","volume":"60","author":"JY Kim","year":"2006","unstructured":"Kim, J.Y., Jung, H.I., An, Y.J., Lee, J.H., Kim, S.J., Jeong, S.H., Lee, K.J., Suh, P.G., Lee, H.S., Lee, S.H., et al. 2006. Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C \u03b2-lactamase. Mol. Microbiol.60, 907\u2013916.","journal-title":"Mol. Microbiol."},{"key":"285_CR52","doi-asserted-by":"crossref","first-page":"8544","DOI":"10.1021\/acs.jmedchem.9b00911","volume":"62","author":"A Krajnc","year":"2019","unstructured":"Krajnc, A., Brem, J., Hinchliffe, P., Calvopi\u00f1a, K., Panduwawala, T.D., Lang, P., Kamps, J.J.A.G., Tyrrell, J.M., Widlake, E., Saward, B.G., et al. 2019. Bicyclic boronate VNRX-5133 inhibits metallo- and serine-\u03b2-Lactamase. J. Med. Chem.62, 8544\u20138556.","journal-title":"J. Med. Chem."},{"key":"285_CR53","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cbpa.2019.03.001","volume":"50","author":"A Krajnc","year":"2019","unstructured":"Krajnc, A., Lang, P.A., Panduwawala, T.D., Brem, J., and Schofield, C.J. 2019. Will morphing boron-based inhibitors beat the \u03b2-lactamases? Curr. Opin. Chem. Biol.50, 101\u2013110.","journal-title":"Curr. Opin. Chem. Biol."},{"key":"285_CR54","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1021\/acs.jmedchem.9b01518","volume":"63","author":"B Liu","year":"2020","unstructured":"Liu, B., Trout, R.E.L., Chu, G.H., McGarry, D., Jackson, R.W., Hamrick, J.C., Diagle, D.M., Cusick, S.M., Pozzi, C., de Luca, F., et al. 2020. Discovery of Taniborbactam (VNRX-5133): a broad-spectrum serine- and metallo-\u03b2-lactamase inhibitor for carbapenem-resistant bacterial infections. J. Med. Chem.63, 2789\u20132801.","journal-title":"J. Med. Chem."},{"key":"285_CR55","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/jac\/dkw593","volume":"72","author":"DM Livermore","year":"2017","unstructured":"Livermore, D.M., Mushtaq, S., Warner, M., Vickers, A., and Woodford, N. 2017. In vitro activity of Cefepime\/Zidebactam (WCK 5222) against Gram-negative bacteria. J. Antimicrob. Chemother.72, 1373\u20131385.","journal-title":"J. Antimicrob. Chemother."},{"key":"285_CR56","first-page":"e02209","volume":"61","author":"SH Lob","year":"2017","unstructured":"Lob, S.H., Hackel, M.A., Kazmierczak, K.M., Young, K., Motyl, M.R., Karlowsky, J.A., and Sahm, D.F. 2017. In vitro activity of imipenem-relebactam against Gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (results from the SMART global surveillance program). Antimicrob. Agents Chemother.61, e02209\u201316.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR57","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/jac\/dkm227","volume":"60","author":"H Mammeri","year":"2007","unstructured":"Mammeri, H., Poirel, L., and Nordmann, P. 2007. Extension of the hydrolysis spectrum of AmpC \u03b2-lactamase of Escherichia coli due to amino acid insertion in the H-10 helix. J. Antimicrob. Chemother.60, 490\u2013494.","journal-title":"J. Antimicrob. Chemother."},{"key":"285_CR58","volume-title":"ASM Microbe","author":"S McLeod","year":"2018","unstructured":"McLeod, S., Carter, N., Hackel, M., Badal, R., Mueller, J., Tommasi, R., and Miller, A. 2018. The novel \u03b2-lactamase inhibitor ETX1317 effectively restores the activity of cefpodoxime against extended spectrum \u03b2-lactamase (ESBL)- and carbapenemase-expressing enterobacteriaceae isolated from recent urinary tract infections. ASM Microbe Atlanta, Georgia, USA. Friday-603."},{"key":"285_CR59","doi-asserted-by":"crossref","unstructured":"McLeod, S., Shapiro, A., Moussa, S., Carter, N., Johnstone, M., McLaughlin, R., Dejonge, B., Tommasi, R., Mueller, J., Miller, A. 2016. Sulbactam combined with the novel \u03b2-lactamase inhibitor ETX2514 for the treatment of multidrug-resistant Acinetobacter baumannii infections. Open Forum Infect. Dis.3, suppl_1.","DOI":"10.1093\/ofid\/ofw172.1794"},{"key":"285_CR60","volume-title":"European Congress of Clinical Microbiology and Infectious Diseases (29th ECCMID), Amsterdam, Netherlands","author":"RE Mendes","year":"2019","unstructured":"Mendes, R.E., Rhomberg, P.R., Watters, A.A., Castanheira, M., and Flamm, R. 2019. In vitro activity of the orally available ceftibuten\/VNRX-7145 combination against a challenge set of Enterobacteriaceae pathogens carrying molecularly characterized \u03b2-lactamase genes. European Congress of Clinical Microbiology and Infectious Diseases (29th ECCMID), Amsterdam, Netherlands. Abs. P1180."},{"key":"285_CR61","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1128\/AAC.01067-16","volume":"60","author":"J Mor\u00e1n-Barrio","year":"2016","unstructured":"Mor\u00e1n-Barrio, J., Lisa, M.N., Larrieux, N., Drusin, S.I., Viale, A.M., Moreno, D.M., Buschiazzo, A., and Vila, A.J. 2016. Crystal structure of the metallo-\u03b2-lactamase GOB in the periplasmic dizinc form reveals an unusual metal site. Antimicrob. Agents Chemother. 60, 6013\u20136022.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR62","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bmc.2007.10.075","volume":"16","author":"S Morandi","year":"2008","unstructured":"Morandi, S., Morandi, F., Caselli, E., Shoichet, B.K., and Prati, F. 2008. Structure-based optimization of cephalothin-analogue boronic acids as \u03b2-lactamase inhibitors. Bioorg. Med. Chem.16, 1195\u20131205.","journal-title":"Bioorg. Med. Chem."},{"key":"285_CR63","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1093\/jac\/dkv166","volume":"70","author":"A Morinaka","year":"2015","unstructured":"Morinaka, A., Tsutsumi, Y., Yamada, M., Suzuki, K., Watanabe, T., Abe, T., Furuuchi, T., Inamura, S., Sakamaki, Y., Mitsuhashi, N., et al. 2015. OP0595, a new diazabicyclooctane: mode of action as a serine \u03b2-lactamase inhibitor, antibiotic and \u03b2-lactam \u2018Enhancer\u2019. J. Antimicrob. Chemother.70, 2779\u20132786.","journal-title":"J. Antimicrob. Chemother."},{"key":"285_CR64","doi-asserted-by":"crossref","first-page":"e00514","DOI":"10.1128\/AAC.00514-19","volume":"63","author":"I Morrissey","year":"2019","unstructured":"Morrissey, I., Magnet, S., Hawser, S., Shapiro, S., and Knechtle, P. 2019. In vitro activity of cefepime-enmetazobactam against Gram-negative isolates collected from U.S. and European hospitals during 2014\u20132015. Antimicrob. Agents Chemother.63, e00514\u201319.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR65","first-page":"e01238","volume":"61","author":"B Moya","year":"2017","unstructured":"Moya, B., Barcelo, I.M., Bhagwat, S., Patel, M., Bou, G., Papp-Wallace, K.M., Bonomo, R.A., and Oliver, A. 2017a. Potent \u03b2-lactam enhancer activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, including carbapenemase-producing clinical isolates. Antimicrob. Agents Chemother.61, e01238\u201317.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR66","first-page":"e02529","volume":"61","author":"B Moya","year":"2017","unstructured":"Moya, B., Barcelo, I.M., Bhagwat, S., Patel, M., Bou, G., Papp-Wallace, K.M., Bonomo, R.A., and Oliver, A. 2017b. WCK 5107 (Zidebactam) and WCK 5153 are novel inhibitors of PBP2 showing potent \u201c\u03b2-lactam enhancer\u201d activity against Pseudomonas aeruginosa, including multidrug-resistant metallo-\u03b2-lactamase-producing high-risk clones. Antimicrob. Agents Chemother.61, e02529\u201316.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR67","volume-title":"European Congress of Clinical Microbiology and Infectious Diseases (28th ECCMID), Madrid Spain","author":"S Mushtaq","year":"2018","unstructured":"Mushtaq, S., Vickers, A., Woodford, N., and Livermore, D. 2018. Potentiation of cefepime by the boronate VNRX-5133 versus Gram-negative bacteria with known \u03b2-lactamases. European Congress of Clinical Microbiology and Infectious Diseases (28th ECCMID), Madrid Spain. Abs. P1536."},{"key":"285_CR68","first-page":"e00098","volume":"61","author":"JH Na","year":"2017","unstructured":"Na, J.H., An, Y.J., and Cha, S.S. 2017. GMP and IMP are competitive inhibitors of CMY-10, an extended-spectrum class C \u03b2-lactamase. Antimicrob. Agents Chemother. 61, e00098\u201317.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR69","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1107\/S2059798316011311","volume":"72","author":"JH Na","year":"2016","unstructured":"Na, J.H. and Cha, S.S. 2016. Structural basis for the extended substrate spectrum of AmpC BER and structure-guided discovery of the inhibition activity of citrate against the class C \u03b2-lactamases AmpC BER and CMY-10. Acta Cryst. D Struct. Biol.72, 976\u2013985.","journal-title":"Acta Cryst. D Struct. Biol."},{"key":"285_CR70","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3389\/fcimb.2018.00441","volume":"8","author":"JH Na","year":"2018","unstructured":"Na, J.H., Lee, T.H., Park, S.B., Kim, M.K., Jeong, B.G., Chung, K.M., and Cha, S.S. 2018. In vitro and in vivo inhibitory activity of NADPH against the AmpC BER class C \u03b2-lactamase. Front. Cell. Infect. Microbiol.8, 441.","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"285_CR71","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2217\/17460913.2.3.297","volume":"2","author":"P Nordmann","year":"2007","unstructured":"Nordmann, P. and Mammeri, H. 2007. Extended-spectrum cephalosporinases: structure, detection and epidemiology. Future Microbiol.2, 297\u2013307.","journal-title":"Future Microbiol."},{"key":"285_CR72","volume-title":"ASM Microbe","author":"J O\u2019Donnell","year":"2017","unstructured":"O\u2019Donnell, J., Chen, A., Tanudra, A., Mueller, J., Tommasi, R., Miller, A., Carter, N., McLeod, S., Comita-Prevoir, J., and Durand-R\u00e9ville, T. 2017. Cefpodoxime proxetil\/ETX0282: a novel oral \u03b2-lactam\/\u03b2-lactamase inhibitor combination to treat the emerging threat of multi-drug resistant Enterobacteriaceae. ASM Microbe, New Orleans, Louisiana, USA."},{"key":"285_CR73","doi-asserted-by":"crossref","first-page":"576297","DOI":"10.1155\/2008\/576297","volume":"2008","author":"MI Page","year":"2008","unstructured":"Page, M.I. and Badarau, A. 2008. The mechanisms of catalysis by metallo \u03b2-lactamases. Bioinorg. Chem. Appl.2008, 576297.","journal-title":"Bioinorg. Chem. Appl."},{"key":"285_CR74","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1080\/14656566.2019.1660772","volume":"20","author":"KM Papp-Wallace","year":"2019","unstructured":"Papp-Wallace, K.M. 2019. The latest advances in \u03b2-lactam-\u03b2-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections. Expert Opin. Pharmacother.20, 2169\u20132184.","journal-title":"Expert Opin. Pharmacother."},{"issue":"suppl_1","key":"285_CR75","doi-asserted-by":"crossref","first-page":"S375","DOI":"10.1093\/ofid\/ofx163.924","volume":"4","author":"KM Papp-Wallace","year":"2017","unstructured":"Papp-Wallace, K.M., Bethel, C.R., Barnes, M.D., Rutter, J.D., Taracila, M.A., Bajaksouzian, S., Jacobs, M.R., and Bonomo, R.A. 2017. AAI101, a novel \u03b2-lactamase inhibitor: microbiological and enzymatic profiling. Open Forum Infect. Dis.4(suppl_1), S375.","journal-title":"Open Forum Infect. Dis."},{"key":"285_CR76","first-page":"e00105","volume":"63","author":"KM Papp-Wallace","year":"2019","unstructured":"Papp-Wallace, K.M., Bethel, C.R., Caillon, J., Barnes, M.D., Potel, G., Bajaksouzian, S., Rutter, J.D., Reghal, A., Shapiro, S., Taracila, M.A., et al. 2019. Beyond piperacillin-tazobactam: cefepime and AAI101 as a potent \u03b2-lactam-\u03b2-lactamase inhibitor combination. Antimicrob. Agents Chemother.63, e00105\u201319.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR77","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.idc.2016.02.007","volume":"30","author":"KM Papp-Wallace","year":"2016","unstructured":"Papp-Wallace, K.M. and Bonomo, R.A. 2016. New \u03b2-lactamase inhibitors in the clinic. Infect. Dis. Clin. North Am.30, 441\u2013464.","journal-title":"Infect. Dis. Clin. North Am."},{"key":"285_CR78","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1021\/acs.jmedchem.8b00091","volume":"61","author":"KM Papp-Wallace","year":"2018","unstructured":"Papp-Wallace, K.M., Nguyen, N.Q., Jacobs, M.R., Bethel, C.R., Barnes, M.D., Kumar, V., Bajaksouzian, S., Rudin, S.D., Rather, P.N., Bhavsar, S., et al. 2018. Strategic approaches to overcome resistance against Gram-negative pathogens using \u03b2-lactamase inhibitors and \u03b2-lactam enhancers activity of three novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234. J. Med. Chem.61, 4067\u20134086.","journal-title":"J. Med. Chem."},{"key":"285_CR79","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1128\/AAC.04808-14","volume":"59","author":"WF Penwell","year":"2015","unstructured":"Penwell, W.F., Shapiro, A.B., Giacobbe, R.A., Gu, R.F., Gao, N., Thresher, J., McLaughlin, R.E., Huband, M.D., DeJonge, B.L.M., Ehmann, D.E., et al. 2015. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob. Agents Chemother.59, 1680\u20131689.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR80","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1128\/AAC.01464-06","volume":"51","author":"F Perez","year":"2007","unstructured":"Perez, F., Hujer, A.M., Hujer, K.M., Decker, B.K., Rather, P.N., and Bonomo, R.A. 2007. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother.51, 3471\u20133484.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR81","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2147\/IDR.S150447","volume":"11","author":"LA Petty","year":"2018","unstructured":"Petty, L.A., Henig, O., Patel, T.S., Pogue, J.M., and Kaye, K.S. 2018. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae. Infect. Drug Resist.11, 1461\u20131472.","journal-title":"Infect. Drug Resist."},{"key":"285_CR82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.46.1.1-11.2002","volume":"46","author":"A Philippon","year":"2002","unstructured":"Philippon, A., Arlet, G., and Jacoby, G.A. 2002. Plasmid-determined AmpC-type \u03b2-lactamases. Antimicrob. Agents Chemother.46, 1\u201311.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR83","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1128\/AAC.33.8.1131","volume":"33","author":"A Philippon","year":"1989","unstructured":"Philippon, A., Labia, R., and Jacoby, G. 1989. Extended-spectrum \u03b2-lactamases. Antimicrob. Agents Chemother.33, 1131\u20131136.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR84","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cmi.2014.12.025","volume":"21","author":"JM Pogue","year":"2015","unstructured":"Pogue, J.M., Kaye, K.S., Cohen, D.A., and Marchaim, D. 2015. Appropriate antimicrobial therapy in the era of multidrug-resistant human pathogens. Clin. Microbiol. Infect.21, 302\u2013312.","journal-title":"Clin. Microbiol. Infect."},{"key":"285_CR85","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1007\/s00018-008-7591-7","volume":"65","author":"RF Pratt","year":"2008","unstructured":"Pratt, R.F. 2008. Substrate specificity of bacterial DD-peptidases (penicillin-binding proteins). Cell. Mol. Life Sci.65, 2138\u20132155.","journal-title":"Cell. Mol. Life Sci."},{"key":"285_CR86","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/antibiotics3020193","volume":"3","author":"W Qin","year":"2014","unstructured":"Qin, W., Panunzio, M., and Biondi, S. 2014. \u03b2-Lactam antibiotics renaissance. Antibiotics3, 193\u2013215.","journal-title":"Antibiotics"},{"key":"285_CR87","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/CMR.00001-07","volume":"20","author":"AM Queenan","year":"2007","unstructured":"Queenan, A.M. and Bush, K. 2007. Carbapenemases: the versatile \u03b2-lactamases. Clin. Microbiol. Rev.20, 440\u2013458.","journal-title":"Clin. Microbiol. Rev."},{"key":"285_CR88","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4103\/0974-777X.68531","volume":"2","author":"D Rawat","year":"2010","unstructured":"Rawat, D. and Nair, D. 2010. Extended-spectrum \u03b2-lactamases in Gram negative bacteria. J. Glob. Infect. Dis.2, 263\u2013274.","journal-title":"J. Glob. Infect. Dis."},{"key":"285_CR89","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1086\/533452","volume":"197","author":"LB Rice","year":"2008","unstructured":"Rice, L.B. 2008. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. J. Infect. Dis.197, 1079\u20131081.","journal-title":"J. Infect. Dis."},{"key":"285_CR90","volume-title":"ASM Microbe","author":"HS Sader","year":"2017","unstructured":"Sader, H.S., Flamm, R.K., Huband, M.D., Rhomberg, P.R., and Castanheira, M. 2017. Antimicrobial activity of meropenem-WCK 4234 (WCK 5999) against clinical isolates of Acinetobacter spp. collected worldwide and stratified by infection type. ASM Microbe, New Orleans, Louisiana, USA."},{"key":"285_CR91","first-page":"e01856","volume":"62","author":"HS Sader","year":"2018","unstructured":"Sader, H.S., Mendes, R.E., Pfaller, M.A., Shortridge, D., Flamm, R.K., and Castanheira, M. 2018. Antimicrobial activities of aztreonam-avibactam and comparator agents against contemporary (2016) clinical Enterobacteriaceae isolates. Antimicrob. Agents Chemother.62, e01856\u201317.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR92","doi-asserted-by":"crossref","first-page":"2475067","DOI":"10.1155\/2016\/2475067","volume":"2016","author":"S Santajit","year":"2016","unstructured":"Santajit, S. and Indrawattana, N. 2016. Mechanisms of antimicrobial resistance in ESKAPE pathogens. Biomed Res. Int.2016, 2475067.","journal-title":"Biomed Res. Int."},{"key":"285_CR93","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.1073\/pnas.0607557104","volume":"104","author":"E Santillana","year":"2007","unstructured":"Santillana, E., Beceiro, A., Bou, G., and Romero, A. 2007. Crystal structure of the carbapenemase OXA-24 reveals insights into the mechanism of carbapenem hydrolysis. Proc. Natl. Acad. Sci. USA104, 5354\u20135359.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"285_CR94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11597960-000000000-00000","volume":"72","author":"C Schultsz","year":"2012","unstructured":"Schultsz, C. and Geerlings, S. 2012. Plasmid-mediated resistance in Enterobacteriaceae: changing landscape and implications for therapy. Drugs72, 1\u201316.","journal-title":"Drugs"},{"key":"285_CR95","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/vde.12362","volume":"28","author":"S Schwarz","year":"2017","unstructured":"Schwarz, S., Loeffler, A., and Kadlec, K. 2017. Bacterial resistance to antimicrobial agents and its impact on veterinary and human medicine. Vet. Dermatol.28, 82\u2013e19.","journal-title":"Vet. Dermatol."},{"key":"285_CR96","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3923\/crb.2009.50.55","volume":"2","author":"SM Shrivastava","year":"2009","unstructured":"Shrivastava, S.M., Kumar, S., and Chaudhary, M. 2009. Ceftriaxone-sulbactam combination: microbial analysis by variation of ratios and comparative disc diffusion. Curr. Res. Bacteriol.2, 50\u201355.","journal-title":"Curr. Res. Bacteriol."},{"key":"285_CR97","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1574-6976.2009.00198.x","volume":"34","author":"A Smet","year":"2010","unstructured":"Smet, A., Martel, A., Persoons, D., Dewulf, J., Heyndrickx, M., Herman, L., Haesebrouck, F., and Butaye, P. 2010. Broad-spectrum \u03b2-lactamases among Enterobacteriaceae of animal origin: molecular aspects, mobility and impact on public health. FEMS Microbiol. Rev.34, 295\u2013316.","journal-title":"FEMS Microbiol. Rev."},{"key":"285_CR98","volume-title":"Probe Reports from the NIH Molecular Libraries Program [Internet]","author":"T Spicer","year":"2014","unstructured":"Spicer, T., Minond, D., Enogieru, I., Saldanha, S.A., Allais, C., Liu, Q., Mercer, B.A., Roush, W.R., and Hodder, P. 2014. ML302, a novel \u03b2-lactamase (BLA) inhibitor. In Probe Reports from the NIH Molecular Libraries Program [Internet]. National Center for Biotechnology Information (US)."},{"key":"285_CR99","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1128\/AAC.00568-10","volume":"54","author":"T Stachyra","year":"2010","unstructured":"Stachyra, T., P\u00e9chereau, M.C., Bruneau, J.M., Claudon, M., Frere, J.M., Miossec, C., Coleman, K., and Black, M.T. 2010. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-\u03b2-lactam \u03b2-lactamase inhibitor. Antimicrob. Agents Chemother. 54, 5132\u20135138.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR100","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ijantimicag.2007.05.019","volume":"30","author":"S Takeda","year":"2007","unstructured":"Takeda, S., Ishii, Y., Hatano, K., Tateda, K., and Yamaguchi, K. 2007. Stability of FR264205 against AmpC \u03b2-lactamase of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents.30, 443\u2013445.","journal-title":"Int. J. Antimicrob. Agents."},{"key":"285_CR101","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1039\/C8MD00342D","volume":"9","author":"KHME Tehrani","year":"2018","unstructured":"Tehrani, K.H.M.E. and Martin, N.I. 2018. \u03b2-lactam\/\u03b2-lactamase inhibitor combinations: an update. Medchemcomm.9, 1439\u20131456.","journal-title":"Medchemcomm."},{"key":"285_CR102","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ijantimicag.2014.12.033","volume":"45","author":"R Testa","year":"2015","unstructured":"Testa, R., Cant\u00f3n, R., Giani, T., Morosini, M.I., Nichols, W.W., Seifert, H., Stefanik, D., Rossolini, G.M., and Nordmann, P. 2015. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against european Gram-negative and Gram-positive clinical isolates. Int. J. Antimicrob. Agents.45, 641\u2013646.","journal-title":"Int. J. Antimicrob. Agents."},{"key":"285_CR103","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0168-6445(99)00039-X","volume":"24","author":"C Therrien","year":"2000","unstructured":"Therrien, C. and Levesque, R.C. 2000. Molecular basis of antibiotic resistance and \u03b2-lactamase inhibition by mechanism-based inactivators: perspectives and future directions. FEMS Microbiol. Rev.24, 251\u2013262.","journal-title":"FEMS Microbiol. Rev."},{"key":"285_CR104","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41579-020-0340-0","volume":"18","author":"U Theuretzbacher","year":"2020","unstructured":"Theuretzbacher, U., Bush, K., Harbarth, S., Paul, M., Rex, J.H., Tacconelli, E., and Thwaites, G.E. 2020. Critical analysis of antibacterial agents in clinical development. Nat. Rev. Microbiol.18, 286\u2013298.","journal-title":"Nat. Rev. Microbiol."},{"key":"285_CR105","doi-asserted-by":"crossref","first-page":"31913","DOI":"10.1074\/jbc.M104742200","volume":"276","author":"JH Toney","year":"2001","unstructured":"Toney, J.H., Hammond, G.G., Fitzgerald, P.M., Sharma, N., Balkovec, J.M., Rouen, G.P., Olson, S.H., Hammond, M.L., Greenlee M.L., and Gao, Y.D. 2001. Succinic acids as potent inhibitors of plasmid-borne IMP-1 metallo-\u03b2-lactamase. J. Biol. Chem.276, 31913\u201331918.","journal-title":"J. Biol. Chem."},{"key":"285_CR106","first-page":"e00130","volume":"64","author":"R Tsivkovski","year":"2020","unstructured":"Tsivkovski, R., Totrov, M., Lomovskaya, O. 2020. Biochemical characterization of QP7728, a new ultrabroad-spectrum \u03b2-lactamase inhibitor of serine and metallo-\u03b2-lactamases. Antimicrob. Agents Chemother.64, e00130\u201320.","journal-title":"Antimicrob. Agents Chemother."},{"key":"285_CR107","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-018-0141-x","volume":"17","author":"M Tyers","year":"2019","unstructured":"Tyers, M. and Wright, G.D. 2019. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nat. Rev. Microbiol.17, 141\u2013155.","journal-title":"Nat. Rev. Microbiol."},{"key":"285_CR108","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrmicro2677","volume":"10","author":"A Typas","year":"2011","unstructured":"Typas, A., Banzhaf, M., Gross, C.A., and Vollmer, W. 2011. From the regulation of peptidoglycan synthesis to bacterial growth and morphology. Nat. Rev. Microbiol.10, 123\u2013136.","journal-title":"Nat. Rev. Microbiol."},{"key":"285_CR109","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.4155\/fmc-2016-0078","volume":"8","author":"DY Wang","year":"2016","unstructured":"Wang, D.Y., Abboud, M.I., Markoulides, M.S., Brem, J., and Schofield, C.J. 2016. The road to avibactam: the first clinically useful non-\u03b2-lactam working somewhat like a \u03b2-lactam. Future Med. Chem.8, 1063\u20131084.","journal-title":"Future Med. Chem."},{"key":"285_CR110","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","volume":"22","author":"Y Wang","year":"2020","unstructured":"Wang, Y., Wang, J., Wang, R., and Cai, Y. 2020. Resistance to ceftazidime-avibactam and underlying mechanisms. J. Glob. Antimicrob. Resist.22, 18\u201327.","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"285_CR111","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.bmcl.2016.02.007","volume":"26","author":"Y Yusof","year":"2016","unstructured":"Yusof, Y., Tan, D.T.C., Arjomandi, O.K., Schenk, G., and McGeary, R.P. 2016. Captopril analogues as metallo-\u03b2-lactamase inhibitors. Bioorg. Med. Chem. Lett.26, 1589\u20131593.","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"285_CR112","doi-asserted-by":"crossref","first-page":"12478","DOI":"10.3390\/molecules171112478","volume":"17","author":"A Zervosen","year":"2012","unstructured":"Zervosen, A., Sauvage, E., Fr\u00e8re, J.M., Charlier, P., and Luxen, A. 2012. Development of new drugs for an old target-the penicillin binding proteins. Molecules17, 12478\u201312505.","journal-title":"Molecules"},{"key":"285_CR113","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","volume":"73","author":"GG Zhanel","year":"2013","unstructured":"Zhanel, G.G., Lawson, C.D., Adam, H., Schweizer, F., Zelenitsky, S., Lagac\u00e9-Wiens, R.S., Denisuik, A., Gin, A.S., Hoban, D.J., Lynch, J.P., et al. 2013. Ceftazidime-avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination. Drugs73, 159\u2013177.","journal-title":"Drugs"}],"container-title":["Journal of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12275-020-0285-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12275-020-0285-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12275-020-0285-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T12:50:18Z","timestamp":1735044618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12275-020-0285-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,27]]},"references-count":113,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["285"],"URL":"https:\/\/doi.org\/10.1007\/s12275-020-0285-z","relation":{},"ISSN":["1225-8873","1976-3794"],"issn-type":[{"value":"1225-8873","type":"print"},{"value":"1976-3794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,27]]},"assertion":[{"value":"1 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}